SCHEMBL2391367

SCHEMBL2391367

c1coc(CNc2ncnc3c2ncn3C2CCCCO2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.73
▸ NPC1 O15118 2/20 0.73
▸ RAB9A P51151 2/20 0.73
▸ CYP1A2 P05177 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ TP53 P04637 4/20 0.57
▸ PAX8 Q06710 2/20 0.57
▸ ADORA3 P0DMS8 2/20 0.57
▸ SLC29A1 Q99808 1/20 0.57
▸ MITF O75030 1/20 0.57
▸ LMNA P02545 1/20 0.57
▸ CCNB2 O95067 1/20 0.56
▸ CDK1 P06493 1/20 0.56
▸ CCNB1 P14635 1/20 0.56
▸ CCNB3 Q8WWL7 1/20 0.56
▸ CYP2C19 P33261 1/20 0.52
▸ HTT P42858 1/20 0.52
▸ ADORA2A P29274 1/20 0.49
▸ ADORA2B P29275 1/20 0.49
▸ ADORA1 P30542 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2390773 0.97 NPC1 (0.68) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL30409552 0.85 SMN1; SMN2 (0.54) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL29659519 0.85 YTHDC1 (0.64) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL20547190 0.85 YTHDC1 (0.64) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL29659534 0.85 YTHDC1 (0.55) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL20547188 0.85 YTHDC1 (0.55) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL30410457 0.85 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL29366631 0.85 NPC1 (1.00) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL218275 0.85 NPC1 (1.00) SMN1; SMN2NPC1RAB9ACYP1A2HPGD
SCHEMBL20547610 0.84 NPC1 (0.52) SMN1; SMN2NPC1RAB9ACYP1A2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250241848-A1 NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR ANTERIOS, INC. (US) 2025-07-31 — — US disclosed
EP-4532498-A1 HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS Univerzita Palackého v Olomouci (CZ) 2025-04-09 — — EP disclosed
WO-2023232171-A1 HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND THERAPY OF CIRCADIAN RHYTHM DISORDERS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2023-12-07 — — WO disclosed
US-20220387299-A1 NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR ANTERIOS, INC. (US) 2022-12-08 — — US disclosed
EP-3341371-B1 ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS UNIV PALACKEHO (CZ) 2022-06-29 — — EP disclosed
US-10774084-B2 Adenine derivatives and their use as UV-photoprotective agents UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2020-09-15 — — US disclosed
EP-3233861-B1 6,8-DISUBSTITUTED-9-(HETEROCYCLYL) PURINES, COMPOSITIONS CONTAINING THESE DERIVATIVES AND THEIR USE IN COSMETIC AND MEDICINAL APPLICATIONS USTAV EXPERIMENTALNI BOTANIKY AV CR V V I (CZ) 2019-04-10 — — EP disclosed
US-20180298004-A1 ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2018-10-18 — — US disclosed
US-10093675-B2 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications USTAV EXPERIMENTALNI BOTANIKY AV CR, V.V.I. (CZ) 2018-10-09 — — US disclosed
EP-3341371-A1 ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS Univerzita Palackého V Olomouci (CZ) 2018-07-04 — — EP disclosed
US-20110224238-A1 6, 9-Disubstituted Purine Derivatives and Their Use for Treating Skin SZUCOVA LUCIE 2011-09-15 — — US disclosed
US-20110224238-A1 6, 9-Disubstituted Purine Derivatives and Their Use for Treating Skin SZUCOVA LUCIE 2011-09-15 — — US disclosed
US-20100234401-A1 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin SZUCOVA LUCIE 2010-09-16 — — US disclosed
US-20100234401-A1 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin SZUCOVA LUCIE 2010-09-16 — — US disclosed
US-20100234401-A1 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin SZUCOVA LUCIE 2010-09-16 — — US disclosed
EP-2043630-A2 6, 9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE FOR TREATING SKIN Institute of Experimental Botany, Academy of Sciences of the Czech Republic (CZ) 2009-04-08 — — EP disclosed
WO-2008008770-A2 6, 9-DISUBSTITUTED PURINE DERIVATIVES AND THEIR USE FOR TREATING SKIN INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2008-01-17 — — WO disclosed
US-20080009508-A1 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2008-01-10 — — US disclosed
US-20080009508-A1 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2008-01-10 — — US disclosed
US-20080009508-A1 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin INSTITUTE OF EXPERIMENTAL BOTANY, ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 2008-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250241848-A1 NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR TSG101, NPC1L1, NPC1 SMN1; SMN2 299/4885NPC1 3/4885RAB9A 417/4885
US-20180298004-A1 ADENINE DERIVATIVES AND THEIR USE AS UV-PHOTOPROTECTIVE AGENTS XPA, ERCC4, UNG SMN1; SMN2 3882/4885NPC1 3189/4885RAB9A 252/4885
US-20100234401-A1 6,9-Disubstituted Purine Derivatives and Their Use For Treating Skin UNG, P2RY6, MPG SMN1; SMN2 3167/4885NPC1 3196/4885RAB9A 1395/4885
US-20220387299-A1 NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR TSG101, NPC1L1, NPC1 SMN1; SMN2 299/4885NPC1 3/4885RAB9A 417/4885
US-10093675-B2 6,8-disubstituted-9-(heterocyclyl)purines, compositions containing these derivatives and their use in cosmetic and medicinal applications PNP, UNG, NUDT1 SMN1; SMN2 3293/4885NPC1 3580/4885RAB9A 1999/4885
US-20110224238-A1 6, 9-Disubstituted Purine Derivatives and Their Use for Treating Skin UNG, P2RY6, MPG SMN1; SMN2 3167/4885NPC1 3196/4885RAB9A 1395/4885
US-20080009508-A1 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin UNG, P2RY6, MPG SMN1; SMN2 3167/4885NPC1 3196/4885RAB9A 1395/4885
US-10774084-B2 Adenine derivatives and their use as UV-photoprotective agents XPA, ERCC4, UNG SMN1; SMN2 3861/4885NPC1 3283/4885RAB9A 237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback